Literature DB >> 23531791

Comparison of cardiac troponin I and T, including the evaluation of an ultrasensitive assay, as indicators of doxorubicin-induced cardiotoxicity.

William J Reagan1, Malcolm York, Brian Berridge, Eric Schultze, Dana Walker, Syril Pettit.   

Abstract

Cardiac troponin (cTn) has been utilized to assess acute myocardial injury, but the cTn response in active/ongoing chronic injury is not well documented. The purpose of this study was to characterize the cardiac troponin I (cTnI), cardiac troponin T (cTnT), high-sensitivity cTnI, hematology, and clinical chemistry responses in rats treated with doxorubicin. Rats treated with 1, 2, or 3 mg/kg/week (wk) of doxorubicin for 2, 4, or 6 wks were sacrificed after 0, 2, or 4 wks of recovery and compared to untreated controls and animals treated with doxorubicin/dexrazoxane (50 mg/kg/wk) or etoposide (1 and 3 mg/kg/wk). The incidence and mean magnitude of cTn response increased with increasing dose and/or duration of doxorubicin treatment. Conversely, dexrazoxane/doxorubicin was partially protective for cardiotoxicity, and minimal cardiotoxicity occurred with etoposide treatment. Both cTnI and cTnT effectively identified doxorubicin-induced injury as indicated by vacuolation of cardiomyocytes of the atria/ventricles. The association between the cTn responses and histological changes was greater at the higher total exposures, but the magnitude of cTn response did not match closely with histologic grade. The high-sensitivity cTnI assay was also effective in identifying cardiac injury. Alterations occurred in the hematology and clinical chemistry parameters and reflected both dose and duration of doxorubicin treatment.

Entities:  

Keywords:  cardiac troponin; cardiovascular system; clinical pathology; doxorubicin.; rat

Mesh:

Substances:

Year:  2013        PMID: 23531791     DOI: 10.1177/0192623313482056

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  15 in total

1.  Evaluation of potential acute cardiotoxicity of biodegradable nanocapsules in rats by intravenous administration.

Authors:  Rafael Fracasso; Marília Baierle; Gabriela Goëthel; Anelise Barth; Fernando Freitas; Sabrina Nascimento; Louise Altknecht; Virgilio Olsen; Karina Paese; Vinicius Duval da Silva; Iran Castro; Michael Andrades; Nadine Clausell; Adriana Pohlmann; Silvia Guterres; Solange Cristina Garcia
Journal:  Toxicol Res (Camb)       Date:  2015-10-05       Impact factor: 3.524

2.  The effect of tick infestation on the serum concentrations of the cardiac biomarker troponin I, acid-base balance and haematobiochemical profiles in camels (Camelus dromedarius).

Authors:  Mohamed Tharwat; Fahd Al-Sobayil
Journal:  Trop Anim Health Prod       Date:  2013-09-04       Impact factor: 1.559

3.  Exogenous NAD(+) administration significantly protects against myocardial ischemia/reperfusion injury in rat model.

Authors:  Youjun Zhang; Ban Wang; Xingli Fu; Shaofeng Guan; Wenzheng Han; Jie Zhang; Qian Gan; Weiyi Fang; Weihai Ying; Xinkai Qu
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

Review 4.  In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation.

Authors:  Serena L'Abbate; Michela Chianca; Iacopo Fabiani; Annamaria Del Franco; Alberto Giannoni; Giuseppe Vergaro; Chrysanthos Grigoratos; Claudia Kusmic; Claudio Passino; Yuri D'Alessandra; Silvia Burchielli; Michele Emdin; Daniela Maria Cardinale
Journal:  J Cardiovasc Transl Res       Date:  2022-03-21       Impact factor: 4.132

5.  BMP-2 alleviates heart failure with type 2 diabetes mellitus and doxorubicin-induced AC16 cell injury by inhibiting NLRP3 inflammasome-mediated pyroptosis.

Authors:  Jia-Mei Zhang; Rui-Qun Yu; Feng-Zhu Wu; Liang Qiao; Xiao-Rong Wu; Ying-Jie Fu; Yue-Feng Liang; Yu Pang; Chun-Yi Xie
Journal:  Exp Ther Med       Date:  2021-06-23       Impact factor: 2.447

6.  The utility of serum biomarkers to detect myocardial alterations induced by Imatinib in rats.

Authors:  Eugene Herman; Alan Knapton; Jun Zhang; Joel Estis; John Todd; Steven Lipshultz
Journal:  Pharmacol Res Perspect       Date:  2014-03-03

7.  Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study.

Authors:  Yang QuanJun; Yang GenJin; Wan LiLi; Han YongLong; Huo Yan; Li Jie; Huang JinLu; Lu Jin; Gan Run; Guo Cheng
Journal:  PLoS One       Date:  2017-01-10       Impact factor: 3.240

8.  Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion.

Authors:  Raymundo A Quintana; Jose Banchs; Ridhi Gupta; Heather Y Lin; Sean D Raj; Anthony Conley; Vinod Ravi; Dejka Araujo; Robert S Benjamin; Shreyaskumar Patel; Saroj Vadhan-Raj; Neeta Somaiah
Journal:  Sarcoma       Date:  2017-09-26

9.  Doxorubicin-Induced Cardiotoxicity in Collaborative Cross (CC) Mice Recapitulates Individual Cardiotoxicity in Humans.

Authors:  Caroline J Zeiss; Daniel M Gatti; Olga Toro-Salazar; Crystal Davis; Cathleen M Lutz; Francis Spinale; Timothy Stearns; Milena B Furtado; Gary A Churchill
Journal:  G3 (Bethesda)       Date:  2019-08-08       Impact factor: 3.154

10.  Morphine enhances doxorubicin-induced cardiotoxicity in the rat.

Authors:  Lisa Drange Hole; Terje Hjalmar Larsen; Kjell Ove Fossan; Fredrik Limé; Jan Schjøtt
Journal:  Cardiovasc Toxicol       Date:  2014-09       Impact factor: 3.231

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.